Dupixent retakes TV ad spending crown but overall outlay for the top 10 remains lownews2022-05-06T07:18:38+00:00May 6th, 2022|Fierce Pharma|
‘Who wants to make money?’ Court documents outline wild fraud scheme targeting Gilead HIV medsnews2022-05-05T20:09:58+00:00May 5th, 2022|Fierce Pharma|
Novartis halts US production of radioligand cancer therapies, citing potential quality issuesnews2022-05-05T16:20:48+00:00May 5th, 2022|Fierce Pharma|
Novartis halts US production of cancer radiotherapies, citing potential quality issuesnews2022-05-05T16:20:48+00:00May 5th, 2022|Fierce Pharma|
Intercept sells Ocaliva rights outside the US after NASH development woesnews2022-05-05T15:12:54+00:00May 5th, 2022|Fierce Pharma|
Predict Process Conditions with Digital Twin in Manufacturingnews2022-05-05T14:27:37+00:00May 5th, 2022|Fierce Pharma|
AbbVie puts ‘U’ at the center of latest Ubrelvy ad with tennis star Serena Williamsnews2022-05-05T14:11:10+00:00May 5th, 2022|Fierce Pharma|
Marinus restarts phase 3 seizure trials after stability, COVID delaysnews2022-05-05T13:58:49+00:00May 5th, 2022|Fierce Pharma|
On a roll, AstraZeneca’s Ultomiris hits goal in rare autoimmune diseasenews2022-05-05T13:53:38+00:00May 5th, 2022|Fierce Pharma|
Amid BeiGene’s global expansion push, CEO Oyler scores 16% pay raise to $16.7Mnews2022-05-05T13:11:29+00:00May 5th, 2022|Fierce Pharma|
